Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysisCapsule Summary

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysisCapsule Summary

Janus kinase (JAK) inhibitors block pathways involved in inflammation and immune response, making JAK inhibitors useful in the treatment of various diseases. While the efficacy of these drugs has been proven in several studies, their safety profile needs to be further investigated. In this systemati...

Full description

Bibliographic Details
Main Authors: Daniel Isufi, BSc(Med), Mikkel Bak Jensen, MD, Nikolai Loft, MD, PhD, Lone Skov, MD, PhD, DMSc, Jesper Elberling, MD, PhD, Farzad Alinaghi, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JAAD International
Subjects:
immune-mediated diseases
infections
JAK inhibitors
Janus kinase inhibitor
randomized clinical trials
Online Access:http://www.sciencedirect.com/science/article/pii/S266632872400169X

Internet

http://www.sciencedirect.com/science/article/pii/S266632872400169X

Similar Items